Zacks Research Comments on Agios Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at Zacks Research decreased their Q1 2025 earnings estimates for Agios Pharmaceuticals in a report released on Monday, September 9th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.66) for the quarter, down from their previous forecast of ($1.58). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($1.62) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.70) EPS, Q3 2025 earnings at ($1.74) EPS, FY2025 earnings at ($6.75) EPS, Q1 2026 earnings at ($1.56) EPS, Q2 2026 earnings at ($1.50) EPS and FY2026 earnings at ($5.62) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.51) EPS.

A number of other equities analysts have also issued reports on AGIO. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, June 4th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $51.33.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $44.31 on Wednesday. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -7.01 and a beta of 0.75. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $50.35. The business’s 50-day simple moving average is $45.31 and its 200 day simple moving average is $38.54.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $37,000. Quest Partners LLC bought a new position in Agios Pharmaceuticals in the 2nd quarter worth about $40,000. NEOS Investment Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $210,000. North Star Asset Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $216,000. Finally, XTX Topco Ltd acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $230,000.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.